Why the study?
Soluble (pro)renin receptor (s(P)RR) is a candidate biomarker of RAAS activation, but previous studies linked elevated levels in HFrEF to renal dysfunction rather than symptomatic HF or edema.
Does direct renin inhibition with aliskiren reduce plasma s(P)RR levels and prevent symptomatic HFrEF in a mouse model of DCM?
Does direct renin inhibition with aliskiren reduce plasma s(P)RR levels and prevent symptomatic HFrEF in a mouse model of DCM?
Elevated plasma s(P)RR levels in HFrEF are driven by increased plasma renin activity and associated with systemic edema, which can be prevented by direct renin inhibition in a preclinical model.
Answers are grounded in this paper and cite their sources.
s(P)RR may aid RAAS assessment in HFrEF; leaves open independence from renal dysfunction and requires validation before clinical use.
Symptomatic heart failure with reduced ejection fraction (HFrEF) is characterized by edema and chronic pathological activation of the classical renin-angiotensin-aldosterone system (RAAS). The soluble (pro)renin receptor (s(P)RR) is released into circulation by proteolytic cleavage of tissue expressed (P)RR and is a candidate biomarker of RAAS activation. However, previous studies linked elevated levels of s(P)RR in patients with HFrEF to renal dysfunction. Utilizing prospectively enrolled patients with comparable rEF, we show that increased plasma levels of s(P)RR are associated with symptomatic HF (characterized by edema), independent of chronic renal dysfunction. We also found that s(P)RR levels were positively correlated with patient plasma renin activity (PRA). Normotensive mice with dilated cardiomyopathy (DCM) and HFrEF, without renal dysfunction, showed plasma s(P)RR and PRA patterns similar to human HFrEF patients. Plasma s(P)RR levels positively correlated with PRA and systemic edema, but not with EF, resembling findings in patients with HFrEF without chronic kidney dysfunction. In female DCM mice with elevated PRA levels and plasma s(P)RR levels, a randomized, blinded trial comparing the direct renin inhibitor, aliskiren vs. vehicle control, showed that direct renin inhibition normalized PRA, lowered s(P)RR, and prevented symptomatic HFrEF. Considered in light of previous findings, these data suggest that, in HFrEF, in the absence of renal dysfunction, elevation of plasma s(P)RR levels is caused by increased PRA and associated with the development of systemic edema.
No takes yet. Share an insight, caveat, or question.
Gladysheva et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: